Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanomaMichele Del Vecchio, Michele Maio, Lorenza Di Guardo et al.|European Journal of Cancer|2013Cited by 157
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialGeorgina V. Long, Paolo A. Ascierto, Jason J. Luke et al.|The Lancet Oncology|2022Cited by 149
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanomaMichele Maio, Paolo A. Ascierto, Riccardo Danielli et al.|Annals of Oncology|2013Cited by 141
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 StudyJason J. Luke, Georgina V. Long, Matteo S. Carlino et al.|Journal of Clinical Oncology|2024Cited by 106
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Corrado Ficorella, Graziella Pinotti et al.|European Journal of Cancer|2020Cited by 71